BCAN's Patient Handbook - Bladder Cancer Basics for the Newly Diagnosed



Donate Now to Support the Bladder Cancer Advocacy Network



Join The Online Bladder Cancer Support Community



The Bladder Cancer Advocacy Network (BCAN) is proud to announce that we have been designated a Marine Corps Marathon (MCM) Charity Partner! BCAN has been allocated 25 guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013; an event that sold out in 2 hours and 41 minutes in 2012.
  • We are looking at building “Team BCAN” to not only run in the event and raise awareness for bladder cancer but to raise needed funds for fostering research and patient education. According to the Marine Corps Marathon, there is not a required qualifying time to participate in the event, but all runners should maintain at least a 14 minute mile pace. In order to become a member of “Team BCAN” and officially have a slot in this year’s race, you must be registered through BCAN.
  • No federal or Marine Corps endorsement is implied.
  • If you are interested in becoming a member of BCAN’s team or have any questions, please contact Larry Rzepka, BCAN’s Executive Director, at lrzepka@bcan.org.
  • nielsen-photo_cropped1

    Matthew Nielsen, M.D.
    Assistant Professor Urologic Surgery
    University of North Carolina at Chapel Hill

    Dr. Matthew Nielsen completed his undergraduate studies at the University of Kansas, received his medical degree at the Johns Hopkins University School of Medicine and completed his residency training at the Brady Urological Institute of the Johns Hopkins Hospital under Dr. Patrick Walsh.  He is currently an Assistant Professor of Urologic Surgery at the University of North Carolina at Chapel Hill and is a member of the Multidisciplinary Genitourinary Oncology Group at the Lineberger Comprehensive Cancer Center.
    Dr. Nielsen has a major interest not only in the direct care of bladder cancer patients but also in clinical and translational research studying treatment outcomes and developing molecular biological tools to improve risk stratification and tailor treatment selection.    He has authored numerous articles and book chapters on prostate, bladder and kidney cancer and serves as a reviewer for Cancer, Urology, The Journal of Urology, and the British Journal of Urology.
    Click here for more information.